--- title: "7 Analysts Have This To Say About DexCom" type: "News" locale: "en" url: "https://longbridge.com/en/news/275896619.md" description: "DexCom (NASDAQ:DXCM) has received mixed ratings from 7 analysts over the past three months, with an average 12-month price target of $77.14. Recent evaluations show a range of sentiments, with some analysts maintaining or raising their ratings while others have lowered them. Key insights include a revenue growth rate of 21.64% and a net margin of 23.47%. However, the company has a debt-to-equity ratio of 0.94, indicating substantial debt. Analysts' ratings are crucial for investors, reflecting expert opinions on stock performance and future expectations." datetime: "2026-02-13T12:01:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275896619.md) - [en](https://longbridge.com/en/news/275896619.md) - [zh-HK](https://longbridge.com/zh-HK/news/275896619.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275896619.md) | [繁體中文](https://longbridge.com/zh-HK/news/275896619.md) # 7 Analysts Have This To Say About DexCom DexCom (NASDAQ:DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. **Bullish** **Somewhat Bullish** **Indifferent** **Somewhat Bearish** **Bearish** **Total Ratings** 2 3 1 1 0 **Last 30D** 1 0 0 0 0 **1M Ago** 0 0 0 0 0 **2M Ago** 0 2 0 1 0 **3M Ago** 1 1 1 0 0 Analysts have set 12-month price targets for DexCom, revealing an average target of $77.14, a high estimate of $86.00, and a low estimate of $68.00. Surpassing the previous average price target of $77.00, the current average has increased by 0.18%. ![price target chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770984062_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ## Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive DexCom. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Marie Thibault BTIG Maintains Buy $85.00 $85.00 Matt Miksic Barclays Lowers Underweight $71.00 $80.00 Lee Hambright Bernstein Raises Outperform $86.00 $84.00 Anthony Petrone Mizuho Raises Outperform $78.00 $75.00 Joanne Wuensch Citigroup Raises Buy $77.00 $75.00 Patrick Wood Morgan Stanley Raises Overweight $75.00 $63.00 Daniel Markowitz Evercore ISI Group Announces In-Line $68.00 \- ### Key Insights: - **Action Taken:** Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company. - **Rating:** Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market. - **Price Targets:** Understanding forecasts, analysts offer estimates for DexCom's future value. Examining the current and prior targets provides insight into analysts' changing expectations. For valuable insights into DexCom's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table. Stay up to date on DexCom analyst ratings. ## About DexCom DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies. ### Financial Insights: DexCom **Market Capitalization Analysis:** Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity. **Revenue Growth:** DexCom's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of **21.64%**. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector. **Net Margin:** DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of **23.47%,** the company showcases strong profitability and effective cost management. **Return on Equity (ROE):** DexCom's ROE excels beyond industry benchmarks, reaching **10.71%**. This signifies robust financial management and efficient use of shareholder equity capital. **Return on Assets (ROA):** DexCom's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive **3.83%** ROA, the company effectively utilizes its assets for optimal returns. **Debt Management:** DexCom's debt-to-equity ratio surpasses industry norms, standing at **0.94**. This suggests the company carries a substantial amount of debt, posing potential financial challenges. ## Analyst Ratings: Simplified Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks. Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error. This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [DexCom, Inc. (DXCM.US)](https://longbridge.com/en/quote/DXCM.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Demystifying DexCom: Insights From 12 Analyst Reviews](https://longbridge.com/en/news/278388122.md) - [Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/279226861.md) - [BUZZ-MiniMed rises as FDA clears smartphone‑controlled insulin pump](https://longbridge.com/en/news/279614092.md) - [Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity](https://longbridge.com/en/news/279446168.md) - [Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus](https://longbridge.com/en/news/279245032.md)